Table 3 Ophthalmic history: NVG patients treated with a glaucoma GDD
From: The influence of etiology on surgical outcomes in neovascular glaucoma
ALL | n | PDR | n | RVO | n | Other | n | |
|---|---|---|---|---|---|---|---|---|
VA at presentation (Log Mar) | 1.61 (SD: 0.73) | 120 | 1.66 (SD: 0.73) | 74 | 1.45 (SD: 0.75) | 28 | 1.68 (SD: 0.71) | 18 |
IOP at presentation (mmHg) | 43.7 (SD: 13.5) | 120 | 44.5 (SD:13.7) | 74 | 42.4 (SD: 10.5) | 28 | 42.5 (SD: 16.9) | 18 |
Age at presentation (years)a | 66.9 (SD: 11.7) | 120 | 58.2 (SD: 8.8) | 74 | 72.4 (SD: 11.7) | 28 | 65.4 (SD: 12.4) | 18 |
Non-neovascular Glaucoma before presentation | 30 (25%) | 119 | 13 (17.6%) | 73 | 10 (35.7%) | 28 | 7 (38.9%) | 18 |
Lens Status at presentation | ||||||||
Phakic | 53 (48%) | 110 | 36 (52.9%) | 68 | 11 (45.8%) | 24 | 6 (33.3%) | 18 |
Pseudophakic | 55 (50%) | 110 | 31 (45.6%) | 68 | 13 (54.2%) | 24 | 11 (61.1%) | 18 |
Aphakic | 2 (1.8%) | 110 | 1 (1.5%) | 68 | 0 (0%) | 24 | 1 (5.6%) | 18 |
Intravitreal injection before presentation | 48 (44.9%) | 107 | 56 (75.7%) | 64 | 21 (75%) | 25 | 10 (55.6%) | 18 |
Intravitreal injection at presentation | 69 (53.5%) | 120 | 44 (58.7%) | 74 | 17 (54.8%) | 28 | 8 (34.8%) | 18 |
Panretinal photocoagulation before presentation | 67 (55.8%) | 120 | 48 (64.9%) | 74 | 10 (35.7%) | 28 | 9 (50%) | 18 |
Panretinal photocoagulation at presentation | 19 (14.7%) | 120 | 14 (18.7%) | 74 | 2 (7.1%) | 28 | 3 (16.7%) | 18 |
On no glaucoma meds at presentation | 58 (48.33%) | 120 | 41 (55.4%) | 74 | 11 (39.3%) | 28 | 6 (33.3%) | 18 |
Afferent pupillary defect (APD) at presentation | 9 (22%) | 41 | 3 (15.8%) | 19 | 4 (30.8%) | 13 | 2 (22.2%) | 9 |
Hyphema at presentation | 20 (17%) | 118 | 11 (14.9%) | 74 | 5 (18.5%) | 27 | 4 (23.5%) | 17 |
Vitreous Heme at presentation | 22 (22%) | 99 | 16 (22.5%) | 59 | 3 (11.1%) | 25 | 3 (17.7%) | 15 |
Retinal detachment at presentation | 7 (7.1%) | 99 | 7 (11.7%) | 60 | 0 (0%) | 22 | 2 (11.1%) | 17 |